Amanda G. Young
University of Colorado Anschutz · 38 works · 2,400 citations · h-index 12
Top works
- Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17∼92 Family of miRNA Clusters
- Genome-wide identification of Ago2 binding sites from mouse embryonic stem cells with and without mature microRNAs
- A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
- Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation
- Illumina Synthetic Long Read Sequencing Allows Recovery of Missing Sequences even in the “Finished” C. elegans Genome
- Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Transcriptome Analysis of Neural Progenitor Cells by a Genetic Dual Reporter Strategy
- Erratum: Genome-wide identification of Ago2 binding sites from mouse embryonic stem cells with and without mature microRNAs
- Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
- Genomic basis of recombination suppression in the hybrid between Caenorhabditis briggsae and C. nigoni
- The 2024 International Association for the Study of Lung Cancer Global Survey on Biomarker Testing
- Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assay
- Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors
- Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents
- Abstract 971: Validation of a tumor-naïve circulating tumor DNA (ctDNA) response monitoring panel in advanced non-small cell lung cancer (aNSCLC)
- Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring assay: An exploratory analysis of the IMvigor-010 observation arm.
- Detection of Molecular Residual Disease by Circulating Tumor DNA in Early-Stage Node-Negative Rectal Cancers (CCTG CO.28) Using a Tumor-Informed Assay
- Abstract 5455: Identifying somatic variants with defined confidence level in targeted sequencing of tumor DNA without a matched normal sample
- Biomarker testing of lung cancer in North America versus globally.
- Supplementary Figure S5 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer